Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,531.00    1.00 (0.07%)
Bid:
1,531.00
Ask:
1,532.00
Spread: 1.00 (0.065%)
Market Cap: £3.22b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Director/PDMR Shareholding

26 Sep 2016 10:18

RNS Number : 8036K
Hikma Pharmaceuticals Plc
26 September 2016
Β 

Notification and public disclosure of transactions by persons discharging managerial responsibilities

The attached individual notification made under article 19.1 of the Market Abuse Regulation ("MAR") relates to the purchase by Darhold Limited of Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC. The Chairman and Chief Executive, Vice Chairman and a Non-executive Director are directors of and shareholders in Darhold Limited. This announcement is made in accordance with article 19.3 of MAR.

Said Darwazah

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Said Darwazah

2

Reason for the notification

a)

Position/status

Chairman and Chief Executive Officer / PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each

ID Code: GB00B0LCW083

b)

Nature of the transaction

Β 

Acquisition by Darhold Limited of 50,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC. The Chairman and Chief Executive is a director of and shareholder in Darhold Limited with an equity interest of 21.49%.

c)

Price(s) and volume(s)

Price(s): Β£20.99

Volume(s): 50,000

d)

Aggregated information

Aggregated volume: 50,000

Price: Β£20.99

e)

Date of the transaction

23 September 2016

f)

Place of the transaction

London Stock Exchange (XLON)

Β Mazen Darwazah

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Mazen Darwazah

2

Reason for the notification

a)

Position/status

Executive Vice Chairman / PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each

ID Code: GB00B0LCW083

b)

Nature of the transaction

Β 

Acquisition by Darhold Limited of 50,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC. The Executive Vice Chairman is a director of and shareholder in Darhold Limited with an equity interest of 10.82%.

c)

Price(s) and volume(s)

Price(s): Β£20.99

Volume(s): 50,000

d)

Aggregated information

Aggregated volume: 50,000

Price: Β£20.99

e)

Date of the transaction

23 September 2016

f)

Place of the transaction

London Stock Exchange (XLON)

Mohammed 'Ali' Al-Husry

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Mohammed 'Ali' Al-Husry

2

Reason for the notification

a)

Position/status

Non-executive Director/ PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each

ID Code: GB00B0LCW083

b)

Nature of the transaction

Β 

Acquisition by Darhold Limited of 50,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC. The Non-Executive Director is a director of and shareholder in Darhold Limited with an equity interest of 7.95%.

c)

Price(s) and volume(s)

Price(s): Β£20.99

Volume(s): 50,000

d)

Aggregated information

Aggregated volume: 50,000

Price: Β£20.99

e)

Date of the transaction

23 September 2016

f)

Place of the transaction

London Stock Exchange (XLON)

Β 

Peter Speirs, Company Secretary, Responsible for releasing this announcement

26 September 2016

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
DSHGCGDCLBDBGLL
Date   Source Headline
12th Mar 20127:00 amRNSHolding(s) in Company
14th Feb 20123:00 pmRNSTotal Voting Rights
2nd Feb 201211:14 amRNSHolding(s) in Company
1st Feb 20121:26 pmRNSDirector Declaration
17th Jan 201210:39 amRNSTender Offer
13th Jan 201210:16 amRNSDirector/PDMR Shareholding
12th Jan 201210:07 amRNSTotal Voting Rights
22nd Dec 201110:39 amRNSAdditional Listing
2nd Dec 201111:28 amRNSTender Offer
1st Dec 20114:14 pmRNSHolding(s) in Company
11th Nov 201111:25 amRNSTotal Voting Rights
4th Nov 20117:00 amRNSInterim Management Statement
24th Oct 20115:34 pmRNSDirector/PDMR Shareholding
18th Oct 201112:59 pmRNSDirector/PDMR Shareholding
18th Oct 201112:58 pmRNSDirector/PDMR Shareholding
18th Oct 201112:39 pmRNSDirector/PDMR Shareholding
17th Oct 20119:00 amRNSTender Offer
7th Oct 20111:14 pmRNSBlocklisting Interim Review
6th Oct 20113:26 pmRNSDividend Declaration
3rd Oct 20114:33 pmRNSAcquisition
25th Aug 20117:00 amRNSDirectorate Change
25th Aug 20117:00 amRNSInterim Results
19th Aug 20112:21 pmRNSTrading Statement
26th Jul 201110:54 amRNSTotal Voting Rights
11th Jul 20117:00 amRNSHikma enhances its API sourcing capabilities
1st Jun 20114:01 pmRNSTotal Voting Rights
26th May 201112:03 pmRNSDirector/PDMR Shareholding
25th May 20114:01 pmRNSHolding(s) in Company
17th May 20114:12 pmRNSDirector/PDMR Shareholding
13th May 20112:10 pmRNSDirector/PDMR Shareholding
13th May 20112:04 pmRNSDividend Declaration
12th May 201112:19 pmRNSAGM Statement
12th May 20117:00 amRNSInterim Management Statement
9th May 20115:45 pmRNSDirector/PDMR Shareholding
9th May 201112:04 pmRNSTotal Voting Rights
9th May 201112:01 pmRNSAnnual Information Update
3rd May 20117:00 amRNSStatement re Completion of Acquisition
15th Apr 20117:00 amRNSRe Agreement with Unimark Remedies Limited
14th Apr 20114:04 pmRNSAnnual Information Update
13th Apr 201112:07 pmRNSDirector/PDMR Shareholding
4th Apr 20112:33 pmRNSDirector/PDMR Shareholding
18th Mar 20114:05 pmRNSDirector/PDMR Shareholding
16th Mar 20117:00 amRNSPreliminary Results
2nd Mar 20119:55 amRNSTotal Voting Rights
8th Feb 201112:56 pmRNSTotal Voting Rights
3rd Feb 201110:21 amRNSHolding(s) in Company
24th Jan 20119:00 amRNSAppointments
12th Jan 20115:14 pmRNSTotal Voting Rights
12th Jan 201110:13 amRNSDirector/PDMR Shareholding
10th Jan 20113:47 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.